|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM076441636 |
| 003 |
DE-627 |
| 005 |
20250129111507.0 |
| 007 |
tu |
| 008 |
231222s1995 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed25n0255.xml
|
| 035 |
|
|
|a (DE-627)NLM076441636
|
| 035 |
|
|
|a (NLM)7668182
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Yokoyama, O
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization
|
| 264 |
|
1 |
|c 1995
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 06.10.1995
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Nine patients with persistent urinary incontinence due to neurogenic bladder and intolerable systemic side effects on oral anticholinergic agents were treated with intravesical instillation of oxybutynin hydrochloride. Two tablets (6 mg) dissolved in 10 ml of physiological saline or sterile water were instilled into the bladder two times daily via self intermittent catheterization. The mean bladder capacity increased from 128 to 212 ml 1 month after intravesical instillation of oxybutynin hydrochloride, although this difference was not significant. The bladder was augmented more efficaciously in patients with overactive detrusor than patients with an underactive detrusor. Subjective improvement was recognized in 4 patients. Among 5 patients who discontinued therapy due to ineffective results, maximum urethral closure pressure below 50 cmH2O was seen in 4. Intravesical instillation of oxybutynin hydrochloride was considered to be ineffective clinically in patients with underactive detrusor and low urethral closure pressure. Although no systemic side effects were observed, a decrease of bladder capacity was recognized in 2 patients
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Mandelic Acids
|2 NLM
|
| 650 |
|
7 |
|a Parasympatholytics
|2 NLM
|
| 650 |
|
7 |
|a oxybutynin
|2 NLM
|
| 650 |
|
7 |
|a K9P6MC7092
|2 NLM
|
| 700 |
1 |
|
|a Ishiura, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nakamura, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ohkawa, M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 41(1995), 7 vom: 30. Juli, Seite 521-4
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnas
|
| 773 |
1 |
8 |
|g volume:41
|g year:1995
|g number:7
|g day:30
|g month:07
|g pages:521-4
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 41
|j 1995
|e 7
|b 30
|c 07
|h 521-4
|